Loading stock data…
$3.73+0.09 (+2.47%)
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases.
Passage Bio, Inc. in the Healthcare sector is trading at $3.73 with a market capitalization of $16M. Wall Street consensus targets $15.50 (2 analysts), implying a +315.5% move over the next 12 months. The stock is currently near its 52-week low of $3.29, remaining 46.4% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$10.22M↓ | -$8.88M↑ | -$10.34M↓ | -$8.65M↑ | -$10.33M |
| Net Income | -$7.82M↓ | -$7.56M↑ | -$12.98M↓ | -$7.75M↑ | -$9.38M |
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficienc...